EMYRIA LIMITED — AGM Information 2022

Aug 30, 2022

==> picture [596 x 148] intentionally omitted <==

ASX/Media Release 31 August 2022

Annual General Meeting

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development and care delivery company advises, in accordance with ASX Listing Rule 3.13.1, that it has scheduled the 2021 Annual General Meeting (AGM) of the Company to be held on 25 October 2022.

An item of business at the AGM will be the re-election of directors. The closing date for the receipt of director nominations is Tuesday , 6 September 2022.

Nominations must be received at the Company’s registered office no later than 5.00pm (Perth time) on Tuesday , 6 September 2022.

Release authorised by: Dr Michael Winlo, Managing Director

For further information:

Dr Michael Winlo Managing Director (08) 6559 2800 investors@emyria.com

Lexi O’Halloran Media/Investor Relations+ 61 (0) 404 577 076 Lexi O’Halloran lexi@janemorganmanagement.com.au

Andrew Williams Media Relations +61 (0) 412 614 125 andreww@proflemedia.com.au

About Emyria Limited

Emyria Limited (ACN 625 085 734) is an Australian clinical drug development and care delivery company. Emyria’s Treatments target large unmet needs and are focused on obtaining approval (“registration”) with major global regulators. Emyria’s treatment development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services (Emerald Clinics - www.emeraldclinics.com.au).

==> picture [595 x 65] intentionally omitted <==

==> picture [596 x 72] intentionally omitted <==

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalized care programmes.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “inten d,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.